Document:

exv10w1

 

Exhibit 10.1

OPTION AGREEMENT

BETWEEN:

The
University of British Columbia, a corporation continued
under the University Act of British Columbia and having offices at
IRC 331-2194 Health Sciences Mall, in the City of Vancouver, in
the Province of British Columbia, V6T 1Z3

(the
“University”)

AND:

Genemax
Pharmaceuticals Inc., a corporation
incorporated
under the laws of the State of Delaware and having a business
office at 1260 - 999 West Hastings Street, Vancouver, BC V6C
2W2

(the “Optionee”)

WHEREAS:

A. The University has been engaged in research during the course of which it has
invented, developed and/or acquired certain technology relating to Methods of Enhancing
Expression of MHC-Class 1 Molecules Bearing Endogenous Peptides, and Methods of
Identifying MHC-Class 1 Restricted Antigens Endogenously Processed by a Cellular Secretory
Pathway, which research was undertaken by Dr. Wilfred Jefferies and his research group in the
Biotechnology Laboratory at the University;

B. The Optionee is desirous of the University granting an exclusive world-wide
license to the Optionee to use or cause to be used the Technology to manufacture, distribute,
market, sell and/or license or sublicense products derived or developed from such Technology
and to sell the same to the general public during the term of said license Agreement; and

C. The University is prepared to grant the Optionee an option to obtain the license
with respect to the Technology on the terms and conditions set out hereafter.

     NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration
of the premises and of the mutual covenants herein set forth, the parties hereto have
covenanted
and agreed as follows:

 

 

- 2 -

1.0 DEFINITIONS:

1.1 In this Agreement, unless a contrary intention appears, the following words and

     phrases shall mean:
 

	 	(a)  	“Confidential Information”: any part of the Information which is designated by
the
University as confidential, whether orally or in writing but excluding any part of
the Information:

	 	(i)  	possessed by the Optionee prior to receipt from the
University, other than
through prior disclosure by the University, as evidenced by the Optionee’s
business records;
	 
	 	(ii)  	published or available to the general public otherwise than
through a
breach of this Agreement;
	 
	 	(iii)  	obtained by the Optionee from a third party with a valid
right to disclose
it, provided that said third party is not under a confidentiality
obligation to
the University; or
	 
	 	(iv)  	independently developed by employees, agents or consultants of
the
Optionee who had no knowledge of or access to the University’s
Information as evidenced by the Optionee’s business records;

	 	(b)  	“Date of Commencement” or “Commencement Date”: the 7th day of
September, 1999;
	 
	 	(c)  	“Effective Date of Termination”: the date on which this Agreement is terminated
pursuant to Article 13;
	 
	 	(d)  	“Information”: any and all Technology, the terms and conditions of this
Agreement, and any and all oral, written, electronic or other communications and
other information disclosed or provided by the parties including any and all
analyses or conclusions drawn or derived therefrom regarding this Agreement and
information developed or disclosed hereunder, or any party’s raw materials,
processes, formulations, analytical procedures, methodologies, products, samples
and specimens or functions;
	 
	 	(e)  	“Option Period”: one hundred and eighty days from the Date of Commencement
unless this Agreement is terminated early pursuant to Article 13, in which case it
shall be until the Effective Date of Termination;
	 
	 	(f)  	“Researchers”: Wilfred Jefferies, Gregor Reid, Gabathuler Reinhard, Gerassimos
Kolaitis and Judy Alimonti; and

 

 

- 3 -

	 	(g)  	“Technology”: any and all knowledge, know-how and/or technique or techniques
invented, developed and/or acquired, being invented, developed and/or acquired
prior to the Date of Commencement by the University relating to the technology
described in Appendix “A” hereto, as amended from time to time, including,
without limitation, all research, data, specifications, instructions, manuals, papers
or other materials of any nature whatsoever, whether written or otherwise, relating
to the same.

2.0 PROPERTY RIGHTS IN AND TO THE TECHNOLOGY:

2.1 The parties hereto hereby acknowledge and agree that the University owns any and
all right, title and interest in and to the Technology.

3.0 GRANT OF OPTION:

3.1 Subject to the following conditions being met:

	 	(a)  	that all the Researchers will have waived their rights to receive
compensation from
the University and will receive compensation directly from the Optionee, and that
the following Researchers receive compensation as follows:
	 
	 	   	Shares in Optionee:
	 
	 	   	Gerassimos Kolaitis
            - 100,000 common shares without par value
	 
	 	   	Gregor Reid
                         - 50,000 common shares without par value
	 
	 	   	Judy Alimonti
                      - 50,000 common shares without par value
	 
	 	(b)  	disclosure to the University of the equity compensation by the Optionee to
Wilf
Jefferies and Gabathuler Reinhard; and
	 
	 	(c)  	prior to the exercise of the Option the Researchers execute the Waiver of
Rights
document attached as Appendix “C”;

the University hereby grants to the Optionee an option (the “Option”) to obtain the exclusive,
world-wide license to use and sublicense the Technology and to manufacture, distribute and sell
products based on the Technology on the terms and conditions of the licence agreement attached
as Appendix “B” (the “License Agreement”). The Option shall subsist for the duration of the
Option Period.

3.2 During the Option Period the University shall not grant rights in or to the
Technology to any other party and shall not commercially exploit the Technology either itself or
through any agents or representatives.

3.3 The Option granted herein is personal to the Optionee and is not granted to any
Affiliate as that term is defined in section 1(1) of the Company
Act, RSBC 1996, Chapter 62.

 

 

- 4 -

3.4 Notwithstanding paragraph 3.2 herein, the parties acknowledge and agree that the
University may use the Technology without charge in any manner whatsoever for research,
scholarly publication, educational, or other non-commercial uses.

4.0 OPTIONEE’S ACTIVITIES:

4.1 During the Option Period the Optionee shall use reasonable commercial efforts to
raise equity funding in an amount not less than $1,000,000.00 (Canadian) and investigate the
Technology and the market potential of the Technology. The Optionee shall keep the University
informed of its plans to commercialize and exploit the Technology and will inform the University
at the earliest possible date if the Optionee decides not to exercise the Option granted herein.

5.0 EXERCISE OF OPTION:

5.1 In order to exercise the Option the Optionee shall execute the Licence Agreement
attached as Appendix “B” and carry out all obligations due on execution of the Licence
Agreement.

5.2 In the event that the Optionee does not exercise the Option pursuant to paragraph

5.1 on or before the last day of the Option Period, the parties acknowledge and agree that the
Optionee shall have no further right, title or interest in or to the Technology and that the
University may deal with the Technology in any way without further obligation to the Optionee.

5.3 It shall be a condition of the Optionee exercising the Option that it shall have
completed the equity financing as set out in paragraph 4.1.

6.0 DISCLAIMER OF WARRANTY:

6.1 The University makes no representations, conditions or warranties, either express
or implied, with respect to the Technology. Without limiting the generality of the foregoing, the
University specifically disclaims any implied warranty, condition or representation that the
Technology:

	 	(a)  	shall correspond with a particular description;

	 
	 	(b)  	is of merchantable quality;
	 
	 	(c)  	is fit for a particular purpose; or
	 
	 	(d)  	is durable for a reasonable period of time.

6.2 The University shall not be liable for any loss, whether direct, consequential,
incidental or special, which the Optionee suffers arising from any defect, error, fault or failure
to perform with respect to the Technology, even if the University has been advised of the

 

 

-5-

possibility of such defect, error, fault or failure. The Optionee acknowledges that it has
been
advised by the University to undertake its own due diligence with respect to the Technology.

6.3 Nothing in this Agreement shall be construed as:

	 	(a)  	a warranty or representation by the University as to title to the Technology or
that
anything made, used, sold or otherwise disposed of under any license resulting
from the Option granted in this Agreement is or will be free from infringement of
patents, copyrights, trade-marks, industrial design or other intellectual property
rights; or
	 
	 	(b)  	an obligation by the University to bring or prosecute or defend actions or
suits
against third parties for infringement of patents, copyrights, trade-marks,
industrial
designs or other intellectual property or contractual rights with respect to the
Technology.

7.0 INDEMNITY AND LIMITATION OF LIABILITY:

7.1 The Optionee hereby indemnifies, holds harmless and defends the University, its
Board of Governors, officers, employees, faculty, students, invitees and agents against any and
all claims (including all legal fees and disbursements incurred in association therewith) arising
out of the exercise of any rights under this Agreement including, without limiting the generality
of the foregoing, against any damages or losses, consequential or otherwise, arising from or out
of the Option granted herein howsoever the same may arise.

7.2 Subject to paragraph 7.3, the University’s total liability, whether under the express
or implied terms of this Agreement, in tort (including negligence), or at common law, for any loss
or damage suffered by the Optionee, whether direct, indirect, special, or any other similar or like
damage that may arise or does arise from any breaches of this Agreement by the University, its
Board of Governors, officers, employees, faculty, students or agents, shall be limited to the sum
of $5,000.00 (Canadian).

7.3 In no event shall the University be liable for consequential or incidental damages
arising from any breach or breaches of this Agreement.

7.4 No action, whether in contract or tort (including negligence), or otherwise arising
out of or in connection with this Agreement, may be brought by the Optionee more than six
months after the cause of action has occurred.

8.0 CONFIDENTIALITY:

8.1 The Information shall be developed, received, and used by the Optionee solely in
furtherance of the purposes set forth in this Agreement subject to the terms and conditions set
forth in this Article 8.0.

 

 

-6-

8.2 The Optionee shall keep and use all of the Confidential Information in confidence
and shall not, without the University’s prior written consent, disclose any Confidential
Information to any person or entity, except those of the Optionee’s officers, employees,
professional advisors, consultants, servants, agents and assigns who require said Confidential
Information in performing their obligations under this Agreement or in connection with services
provided to the Optionee in conjunction with this Agreement. The Optionee covenants and
agrees that it will initiate and maintain an appropriate internal program limiting the internal
distribution of the Confidential Information to its officers, employees, professional advisors,
consultants, servants or agents and to take the appropriate non-disclosure agreements from any
and all persons who may have access to the Confidential Information.

8.3 The Optionee shall not use, either directly or indirectly, any Confidential
Information for any purpose other than as set forth herein without the University’s prior written
consent, such consent not to be unreasonably withheld.

8.4 In the event that the Optionee is required by judicial or administrative process to
disclose any or all of the Confidential Information, the Optionee shall promptly notify the
University and allow the University reasonable time to oppose such process before disclosing any
Confidential Information.

8.5 Notwithstanding any termination or expiration of this Agreement, the obligations
created in this Article 8.0 shall survive and be binding upon the Optionee, its successors and
assigns.

8.6 The Optionee requires of the University, and the University agrees insofar as it may
be permitted to do so at law, that this Agreement, and each part of it, is confidential and shall
not
be disclosed to third parties, as the Optionee claims that such disclosure would or could reveal
commercial, scientific or technical information and would significantly harm the Optionee’s
competitive position and/or interfere with the Optionee’s negotiations with prospective
sublicensees. Notwithstanding anything contained in this Article, the parties hereto acknowledge
and agree that the University may identify the title of this Agreement, the parties to this
Agreement, the inventors of the Technology, the term of this Agreement and the consideration
granted to the University pursuant to this Agreement.

9.0 ASSIGNMENT:

9.1 The Optionee shall not assign, transfer, mortgage, charge, pledge, hypothecate or
otherwise dispose of any or all of the rights, duties or obligations granted to it under this
Agreement without the prior written consent of the University.

9.2 The University shall have the right to assign its rights, duties and obligations under
this Agreement to a company or society of which it is the sole shareholder in the case of a
company or of which it controls the membership, in the case of a society. In the event of such
an assignment the Optionee will release, remise and forever discharge the University from any
and all obligations or covenants, provided however that such company or society, as the case may

 

 

- 7 -

be, executes a written
agreement which provides that such company or society shall assume all such obligations or covenants from the University and that the Optionee shall retain all rights
granted to the Optionee pursuant to this Agreement.

10.0 GOVERNING LAW AND ARBITRATION:

10.1 This Agreement shall be governed by and construed in accordance with the laws
of the Province of British Columbia and the laws of Canada in force therein without regard to its
conflict of law rules. All parties agree that by executing this Agreement they have attorned to the
jurisdiction of the Supreme Court of British Columbia. Subject to paragraphs 10.2 and 10.3, the
British Columbia Supreme Court shall have exclusive jurisdiction over this Agreement.

10.2 In the event of any dispute arising between the parties concerning this Agreement,
its enforceability or the interpretation thereof, the same shall be settled by a single arbitrator
appointed pursuant to the provisions of the Commercial Arbitration Act of British Columbia, or
any successor legislation then in force. The place of arbitration shall be Vancouver, British
Columbia. The language to be used in the arbitration proceedings shall be English.

10.3 Clause 10.2 of this Article shall not prevent a party hereto from applying to a court
of competent jurisdiction for interim protection such as, by way of example, an interim injunction.

11.0 NOTICES:

11.1 All payments, reports and notices or other documents that any of the parties hereto
are required or may desire to deliver to any other party hereto may be delivered only by personal
delivery or by registered or certified mail, telex or telecopy, all postage and other charges
prepaid,
at the address for such party first set forth above or at such other address as any party may
hereinafter designate in writing to the other party. Any notice personally delivered or sent by
telex or telecopy shall be deemed to have been given or received at the time of delivery, telexing
or telecopying. Any notice mailed as aforesaid shall be deemed to have been received on the
expiration of five calendar days after it is posted, provided that if there shall be at the time of
mailing or between the time of mailing and the actual receipt of the notice a mail strike, slow
down or labour dispute which might affect the delivery of the notice by the mails, then the notice
shall only be effected if actually received.

12.0 TERM:

12.1 This Agreement will be deemed to have come into force on the Date of
Commencement. This Agreement and the Option granted hereunder shall remain in effect for the
duration of the Option Period and shall terminate upon the conclusion of the Option Period
subject to earlier termination pursuant to Article 13 herein.

 

 

-8-

13.0 TERMINATION:

13.1 This Agreement shall automatically and immediately terminate without notice to
the Optionee if any proceeding under the Bankruptcy and Insolvency Act of Canada, or any other
statute of similar purport, is commenced by or against the Optionee.

13.2 The University may, at its option, terminate this Agreement immediately on the
happening of any one or more of the following events by delivering notice in writing to that effect
to the Optionee:

	 	(a)  	if the Optionee becomes insolvent;
	 
	 	(b)  	if any execution, sequestration or any other process of any court becomes
enforceable against the Optionee or if any such process is levied on the rights
under this Agreement or upon any of the monies due to the University and is not
released or satisfied by the Optionee within 30 calendar days thereafter;
	 
	 	(c)  	if any resolution is passed or order made or other steps taken for the winding
up,
liquidation or other termination of the existence of the Optionee;
	 
	 	(d)  	if the Optionee ceases or threatens to cease to carry on its business;
	 
	 	(e)  	if any part of the Optionee’s business relating to this Agreement is
transferred to
a subsidiary or associated company without the prior written consent of the
University, such consent not to be unreasonably withheld except as provided in
paragraph 13.3.

13.3 The University shall not withhold its consent pursuant to subparagraph 13.2(e)
unless the granting of such consent would result in the University having a contractual
relationship with an entity with whom the University is prohibited from contracting with pursuant
to its then existing published policies.

13.4 Other than as set out in paragraphs 13.1 and 13.2, if either party shall be in default
under or shall fail to comply with the terms of this Agreement then the non-defaulting party shall
have the right to terminate this Agreement by written notice to that effect if:

	 	(a)  	such default is reasonably curable within 30 calendar days after receipt of
notice
of such default and such default or failure to comply is not cured within 30
calendar days after receipt of written notice thereof; or
	 
	 	(b)  	such default is not reasonably curable within 30 calendar days after receipt
of
written notice thereof, and such default or failure to comply is not cured within

 

 

-9-

	 	   	such further reasonable period of time as may be necessary for the curing of such
default or failure to comply.

13.5 The Optionee may terminate this Agreement and the Option granted herein at any
time during the Option Period by providing written notice to the University.

14.0 MISCELLANEOUS COVENANTS OF LICENSEE:

14.1 The Optionee hereby represents and warrants to the University that the Optionee
is a corporation duly organized, existing, and in good standing under the laws of the State of
Delaware and has the power, authority, and capacity to enter into this Agreement and to carry out
the transactions contemplated by this Agreement, all of which have been duly and validly
authorized by all requisite corporate proceedings.

14.2 The Optionee represents and warrants that it will, upon its decision to execute the
License Agreement, have the expertise necessary to handle the Technology with care and without
danger to the Optionee, its employees, agents, or the public. The Optionee shall not accept
delivery of the Technology until it has requested and received from the University all necessary
information and advice to ensure that it is capable of handling the Technology in a safe and
prudent manner.

14.3 The Optionee shall comply with all laws, regulations and ordinances, whether
Federal, Provincial, Municipal or otherwise, with respect to the Technology and/or this
Agreement.

15.0 GENERAL:

15.1 Nothing contained herein shall be deemed or construed to create between the
parties hereto a partnership or joint venture. No party shall have the authority to act on behalf
of
any other party, or to commit any other party in any manner or cause whatsoever or to use any
other party’s name in any way not specifically authorized by this Agreement. No party shall be
liable for any act, omission, representation, obligation or debt of any other party, even if
informed
of such act, omission, representation, obligation or debt.

15.2 Subject to the limitations hereinbefore expressed, this Agreement shall enure to
the benefit of and be binding upon the parties and their respective successors and permitted
assigns.

15.3 No condoning, excusing or overlooking by any party of any default, breach or
non-observance by any other party at any time or times in respect of any covenants, provisos or
conditions of this Agreement shall operate as a waiver of such party’s rights under this Agreement
in respect of any continuing or subsequent default, breach or non-observance, so as to defeat in
any way the rights of such party in respect of any such continuing or subsequent default or breach
and no waiver shall be inferred from or implied by anything done or omitted by such party, save
only an express waiver in writing.

 

 

-10-

15.4 No exercise of a specific right or remedy by any party precludes it from or
prejudices it in exercising another right or pursuing another remedy or maintaining an action to
which it may otherwise be entitled either at law or in equity.

15.5 Marginal headings as used in this Agreement are for the convenience of reference
only and do not form a part of this Agreement and are not to be used in the interpretation hereof.

15.6 The terms and provisions, covenants and conditions contained in this Agreement
which by the terms hereof require their performance by the parties hereto after the expiration or
termination of this Agreement shall be and remain in force notwithstanding such expiration or
other termination of this Agreement or any provision thereof for any reason whatsoever.

15.7 In the event that any Article, section, clause, paragraph or subparagraph of this
Agreement shall be held to be indefinite, invalid, illegal or otherwise voidable or unenforceable,
the entire agreement shall not fail on account thereof, and the balance of the Agreement shall
continue in full force and effect.

15.8 The parties hereto each acknowledges that they have not relied upon any advice
or from the other with respect to this Agreement and that they have sought and obtained
independent legal with respect to same.

15.9 The appendices to this Agreement together with the terms and conditions contained
within this Agreement constitute the entire understanding between the parties hereto and no
modifications hereof shall be binding unless executed in writing by the parties hereto. The
appendices will be binding upon the parties hereto except to the extent that they may conflict with
the terms and conditions contained within this Agreement itself, in which case the terms and
conditions of this Agreement shall govern.

15.10 Time shall be of the essence of this Agreement.

 

 

-11-

15.11 Whenever the singular or masculine or neuter is used throughout this Agreement
the same shall be construed as meaning the plural or feminine or body
corporate when the context or the parties hereto may require.

          IN WITNESS WHEREOF the parties hereto have hereunto executed this
Agreement on or about the 14 day of September 1999 but effective as of the Date of
Commencement.

	 	 	 	 	 
	Signed for and on behalf of

	 	 	)	 
	The
University of British Columbia

	 	 	)	 
	by its duly authorized officers:

	 	 	)	 
	 
	 	 	 	 
	

	 	 	)	 
	

	 	 	)	 
	          /s/ Angus Livingstone

	 	 	)	 
		 	 	)	          Managing Director

		 	 	)	University- Industry Liaison Office

	

	 	 	)	 
	Authorized Signatory

	 	 	)	 
	 
	 	 	 	 
	

	 	 	)	 
	Authorized Signatory

	 	 	)	 
	 
	 	 	 	 
	 
	 	 	 	 
	Signed for and on behalf of the

	 	 	)	 
	Genemax
Pharmaceuticals Inc.

	 	 	)	 
	by its duly authorized officer:

	 	 	)	 
	 
	 	 	 	 
	/s/ Ronald L. Handford
	 	 	 	 
	

	 	 	)	 
	Authorized Signatory

	 	 	)	 

 

 

-12-

APPENDIX “A”

Description of
“Technology”

UILO 95-015 Method of Enhancing Expression of MHC-Class 1 Molecules Bearing Endogenous
Peptides and any and all improvements, variations, updates, modifications, and enhancements
thereto, and

UILO 95-010 Method of Identifying MHC-Class 1 Restricted Antigens Endogenously Processed
by a Cellular Secretory Pathway and any and all improvements, variations, updates,
modifications, and enhancements thereto

Including the following patents

UILO 95-015

US SN 08/817,731 (Application)

Japan SN 510486/1996 (Application)

Europe Designating: France, UK, Germany, Switzerland

SN 95931866.8 (Application)

UILO 95-010

US 5,792,604 (Issued)

Japan SN 532142/1997 (Application)

Europe, Designating all countries: EP 97906062.1 (Application)exv10w2

 

Exhibit 10.2

LICENCE AGREEMENT

	 	 	 	 	 
	BETWEEN:

	 	 	 	 
	 
	 	 	 	 
	

	 	The
University Of British Columbia, a corporation
continued under the University Act of British Columbia and
having its administrative offices at 2075 Wesbrook Mall, in the
City of Vancouver, in the Province of British Columbia, V6T 1W5	 	 
	 
	 	 	 	 
	

	 	(the
“University”)	 	 
	 
	 	 	 	 
	AND:
	 	 	 	 
	 
	 	 	 	 
	

	 	Genemax Pharmaceuticals Inc., a corporation
incorporated under the laws of the State of Delaware and having
a business office at 1260 – 999 West Hastings Street,
Vancouver, BC V6C 2W2	 	 
	 
	 	 	 	 
	 
	 	(the
“Licensee”)	 	 
	 
	 	 	 	 
	AND:

	 	 	 	 
	 
	 	 	 	 
	

	 	Dr. Wilfred A. Jefferies, Professor,
with an office at 2222
 Health Sciences Mall, Vancouver, BC V6T
1Z3	 	 
	 
	 	 	 	 
	

	 	(“Jefferies”)	 	 
	 
	 	 	 	 
	

	 	WHEREAS:	 	 

A. The University has been engaged in research during the course of which it has invented,
developed and/or acquired certain technology relating to Methods of Enhancing Expression of
MHC-Class 1 Molecules Bearing Endogenous Peptides, and Methods of Identifying MHC-Class 1
Restricted Antigens Endogenously Processed by a Cellular Secretory Pathway, which research
was undertaken by Dr. Wilfred Jefferies and his research group in the Biotechnology
Laboratory at the University;

B. The University is desirous of entering into this agreement (the “Agreement”) with the
objective of furthering society’s use of its advanced technology, and to generate further
research in a manner consistent with its status as a non-profit, tax exempt educational
institution; and

C. The Licensee is desirous of the University granting an exclusive world-wide licence to
the Licensee to use or cause to be used the Technology to manufacture, distribute, market,
sell, lease and/or license or sublicense products derived or developed from such technology
and to sell the same to the general public during the term of this Agreement.

 

 

- 2 -

              NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the premises and of the
mutual covenants herein set forth, the parties hereto have covenanted and agreed as follows:

1.0 DEFINITIONS:

1.1 In this Agreement, unless a contrary intention appears, the following words and phrases shall
mean:

	 	(a)  	“Accounting”: an accounting statement setting out in detail how the amount of
Revenue was determined;
	 
	 	(b)  	“Affiliated Company” or “Affiliated Companies”: two or more corporations where
the relationship between them is one in which one of them is a subsidiary of the other,
or both are subsidiaries of the same corporation, or fifty percent (50%) or more of the
voting shares of each of them is owned or controlled beneficially by the same person,
corporation or other legal entity;
	 
	 	(c)  	“Confidential Information”: any part of the Information which is designated by
the University as confidential, whether orally or in writing but excluding any part of
the Information:

	 	(i)  	possessed by the Licensee prior to receipt from the University, other
than through prior disclosure by the University, as evidenced by the
Licensee’s business records;
	 
	 	(ii)  	published or available to the general public otherwise than
through a breach of this Agreement;
	 
	 	(iii)  	obtained by the Licensee from a third party with a valid right to
disclose it, provided that said third party is not under a confidentiality
obligation to the University; or
	 
	 	(iv)  	independently developed by employees, agents or consultants of
the Licensee who had no knowledge of or access to the University’s Information
as evidenced by the Licensee’s business records;

	 	(d)  	“Date of Commencement” or “Commencement Date”: this Agreement will be deemed
to have come into force on the Date of Commencement which shall be the
6 day of March, 2000, and shall be read and construed accordingly;
	 
	 	(e)  	“Effective Date of Termination”: the date on which this Agreement is terminated
pursuant to Article 18;
	 
	 	(f)  	“Improvements”: any and all improvements, variations, updates,
modifications, enhancements and alterations directly related to the Technology which
are invented,

 

 

- 3 -

developed and/or acquired after the Date of Commencement by the University or
the Licensee, their employees, servants, agents, sublicensees or subcontractors,
whether patentable or not, which:

	 	(1)  	if patentable, which claim priority from any of the patents or
patent applications which comprise the Technology and cannot be used or
practised without a license of the Technology; or
	 
	 	(2)  	if not patentable, which relate directly to the Technology;

	 	(7)  	“Information”: any and all Technology and any and all Improvements, the terms
and conditions of this Agreement and any and all oral, written, electronic or other
communications and other information disclosed or provided by the parties including any
and all analyses or conclusions drawn or derived therefrom regarding this Agreement and
information developed or disclosed hereunder, or any party’s raw materials, processes,
formulations, analytical procedures, methodologies, products, samples and specimens or
functions;
	 
	 	(8)  	“Product(s)”: goods manufactured in connection with the use of all or some of
the Technology and/or any Improvement;
	 
	 	(9)  	“Technology”: any and all knowledge, know-how and/or technique or techniques
invented, developed and/or acquired, prior to the Date of Commencement by the
University or the Licensee relating to the technology described in Schedule “A”
hereto, as amended from time to time, including, without limitation, all research,
data, specifications, instructions, manuals, papers or other materials of any
nature whatsoever, whether written or otherwise, relating to same; and
	 
	 	(10)  	“UBC Trade-marks”: any mark, trade-mark, service mark, logo, insignia, seal,
design, symbol, or device used by the University in any manner whatsoever.

2.0 PROPERTY RIGHTS IN AND TO THE TECHNOLOGY:

2.1 The parties hereto hereby acknowledge and agree that the University owns any and all right,
title and interest in and to the Technology, as well as any and all Improvements.

2.2 The Licensee shall, at the request of the University, enter into such further agreements and
execute any and all documents as may be required to ensure that ownership of the Technology and any
Improvements remains with the University.

2.3 On the last working day of June of each and every year during which this Agreement remains in
full force and effect the Licensee shall deliver in writing the details of any and all Improvements
which the Licensee and any sublicensees of the Licensee have developed and/or acquired during the
previous twelve month period.

 

 

- 4 -

3.0 GRANT OF LICENCE:

3.1 In consideration herein, and the covenants on the part of the Licensee contained herein, the
University hereby grants to the Licensee an exclusive world-wide licence to use and sublicense the
Technology and any Improvements and to manufacture, distribute and sell Products on the terms and
conditions hereinafter set forth during the term of this Agreement.

3.2 The licence granted herein is personal to the Licensee and is not granted to any Affiliated
Company or Affiliated Companies.

3.3 The Licensee shall not cross-license the Technology or any Improvements without the prior
written consent of the University.

3.4 Notwithstanding paragraph 3.1 herein, the parties acknowledge and agree that the University may
use the Technology and any Improvements without charge in any manner whatsoever for research,
scholarly publication, educational or other non-commercial uses.

3.5 As part of the consideration for the rights granted by the University to the Licensee
hereunder, the Licensee agrees to pay to the University as an initial licence fee the sum of $
113,627.32 (Canadian funds). The said sum shall be paid concurrently with the execution of this
Agreement. Neither all nor any portion of the said sum shall be refundable to the Licensee under
any circumstances. This sum is equal to all patent costs paid by the University in connection with
the Technology up to February 7th 2000.

3.6 Upon execution of this Agreement the University may register a financing statement with respect
to this Agreement under the provisions of the Personal Property Security Act of British Columbia
and/or under the provisions of similar legislation in those jurisdictions in which the Licensee
carries on business and/or has its chief place of business. All costs associated with the
registrations contemplated by this paragraph 3.6 shall be paid for by the Licensee.

3.7 The Licensee shall give written notice to the University if it is carrying on business and/or
locates its chief place of business in a jurisdiction outside British Columbia prior to beginning
business in that other jurisdiction.

3.8 If the University has registered one or more financing statements as set forth in paragraph
3.6, the Licensee shall give written notice to the University of any and all changes of
jurisdiction within or outside of Canada in which it is carrying on business and/or any and all
changes in jurisdiction of its chief place of business within or outside of Canada and shall file
the appropriate documents in the various provincial Personal Property Registries or similar
registries within or outside of Canada to document such changes in jurisdiction and furnish the
University with a copy of the verification with respect to each such filing within 15 calendar days
after receipt of same. All costs associated with the registrations contemplated by this paragraph
3.8 shall be paid for by the Licensee.

 

 

- 5 -

4.0 EQUITY:

4.1 On or before the date of execution of this Agreement the Licensee shall issue to the University
500,000 common shares (the “Shares”) of the Licensee’s share capital. The Shares shall be free from
any pooling or escrow requirements and hold periods save and except as required by applicable
securities laws. The Licensee shall provide to the University concurrently with the issuance of
the Shares:

	 	(a)  	a written assurance that all applicable securities laws have been complied with
in connection with the issuance of the Shares; and
	 
	 	(b)  	confirmation that the Shares represent 500,000 of the 8,100,000 founders’
common shares in the capital of the Licensee which are to be issued and outstanding in
the share capital of the Licensee prior to the Licensee’s issuance of any further
common shares pursuant to any private and/or public equity financing undertaken by the
Licensee.

5.0 SUBLICENSING:

5.1 The Licensee shall have the right to grant sublicences to Affiliated Companies and other
third parties with respect to the Technology and any Improvements with the prior written consent of
the University, such consent not to be unreasonably withheld. The Licensee will furnish the
University with a copy of each sublicence granted within 30 days after execution.

5.2 Any sublicence granted by the Licensee shall be personal to the sublicensee and shall not be
assignable without the prior written consent of the University. Such sublicences shall contain
covenants by the sublicensee to observe and perform similar terms and conditions to those contained
in this Agreement.

5.3 Prior to the beginning of a sublicence agreement the Licensee shall give written notice to the
University as to which jurisdictions the applicable sublicensee is carrying on business in. Within
five calendar days of being aware of the same the Licensee shall provide written notice to the
University if any sublicensee is carrying on business in a jurisdiction outside of British
Columbia.

5.4 If the University has registered one or more financing statements as set forth in paragraph
3.6, the Licensee shall register a financing change statement under the provisions of the Personal
Property Security Act of British Columbia and/or under the provisions of similar legislation in
those jurisdictions in which each sublicensee carries on business or has its chief place of
business in order to add each sublicensee as an additional debtor to the registration referred to
in paragraph 3.6 forthwith upon execution of each sublicence, and shall furnish the University with
a copy of the verification statement with respect to each such filing within 15 calendar days after
receipt of same. All costs associated with the filings contemplated by this paragraph 5.0 shall be
paid for by the Licensee. The Licensee shall give written notice to the University of any and all
changes of jurisdiction within or outside of Canada in which each sublicensee is carrying on
business and/or any and all changes in jurisdiction of each sublicensee’s chief place of business
and shall file the

 

 

- 6 -

appropriate documents in the various provincial Personal Property Registries or similar
registries within or outside of Canada to document such changes in jurisdiction.

6.0 PATENTS:

6.1 The Licensee shall have the right to identify any process, use or products arising out of the
Technology and any Improvements that may be patentable and the University shall, upon the request
of the Licensee, take all reasonable steps to apply for a patent in the name of the University
provided that the Licensee pays all costs of applying for, registering and maintaining the patent
in those jurisdictions in which the Licensee might designate that a patent is required.

6.2 In the event of the issuance of a patent, the Licensee shall have the right to become, and
shall become the Licensee of the same, all pursuant to the terms contained herein.

6.3 Within 30 calendar days of presentation of receipts and/or invoices by the University to the
Licensee, the Licensee will reimburse the University for all costs incurred with respect to any and
all patents relating to the Technology and any Improvements licensed hereunder, and with respect to
any and all maintenance fees for any and all patents relating to the Technology and any
Improvements licensed hereunder.

6.4 The Licensee will reimburse the University for any patent costs for the Technology incurred
after February 7th 2000. The University will invoice patent costs to the Licensee on a
quarterly basis commencing on the first quarter following the Date of Commencement.

7.0 DISCLAIMER OF WARRANTY:

7.1 The University makes no representations, conditions or warranties, either express or implied,
with respect to the Technology or any Improvements or the Products. Without limiting the generality
of the foregoing, the University specifically disclaims any implied warranty, condition or
representation that the Technology or any Improvements or the Products:

	 	(1)  	shall correspond with a particular description;
	 
	 	(2)  	are of merchantable quality;
	 
	 	(3)  	are fit for a particular purpose; or
	 
	 	(4)  	are durable for a reasonable period of time.

The University shall not be liable for any loss, whether direct, consequential, incidental, or
special which the Licensee suffers arising from any defect, error, fault or failure to perform with
respect to the Technology or any Improvements or Products, even if the University has been advised
of the possibility of such defect, error, fault or failure. The Licensee acknowledges that it has
been advised by the University to undertake its own due diligence with respect to the Technology
and any Improvements.

 

 

- 7 -

7.2 Nothing in this Agreement shall be construed as:

	 	(1)  	a warranty or representation by the University as to title to the Technology
and/or any Improvement or that anything made, used, sold or otherwise disposed of under
the licence granted in this Agreement is or will be free from infringement of patents,
copyrights, trade-marks, industrial design or other intellectual property rights;
	 
	 	(2)  	an obligation by the University to bring or prosecute or defend actions or
suits against third parties for infringement of patents, copyrights, trade-marks,
industrial designs or other intellectual property or contractual rights; or
	 
	 	(3)  	the conferring by the University of the right to use in advertising or
publicity the name of the University or the UBC Trademarks.

7.3 Notwithstanding paragraph 7.2, in the event of an alleged infringement of the Technology or any
Improvements, or any right with respect to the Technology or any Improvements, the Licensee shall
have, upon receiving the prior written consent of the University, the right to prosecute litigation
designed to enjoin infringers of the Technology or any Improvements. Provided that it has first
granted its prior written consent, the University agrees to co-operate to the extent of executing
all necessary documents and to vest in the Licensee the right to institute any such suits, so long
as all the direct or indirect costs and expenses of bringing and conducting any such litigation or
settlement shall be borne by the Licensee and in such event all recoveries shall enure to the
Licensee.

7.4 In the event that any complaint alleging infringement or violation of any patent or other
proprietary rights is made against the Licensee or a sublicensee of the Licensee with respect to
the use of the Technology or any Improvements or the manufacture, use or sale of the Products, the
following procedure shall be adopted:

	 	(1)  	the Licensee shall promptly notify the University upon receipt of any such
complaint and shall keep the University fully informed of the actions and positions
taken by the complainant and taken or proposed to be taken by the Licensee on behalf of
itself or a sublicensee;
	 
	 	(2)  	except as provided in subparagraph 7.4(d), all costs and expenses incurred by
the Licensee or any sublicensee of the Licensee in investigating, resisting, litigating
and settling such a complaint, including the payment of any award of damages and/or
costs to any third party, shall be paid by the Licensee or any sublicensee of the
Licensee, as the case may be;
	 
	 	(3)  	no decision or action concerning or governing any final disposition of the
complaint shall be taken without full consultation with and approval by the University,
such approval not to be unreasonably withheld;
	 
	 	(4)  	the University may elect to participate formally in any litigation involving
the complaint to the extent that the court may permit, but any additional expenses

 

 

- 8 -

generated by such formal participation shall be paid by the University (subject to
the possibility of recovery of some or all of such additional expenses from the
complainant); and

	 	(5)  	notwithstanding paragraph 7.3, if the complainant is willing to accept an
offer of settlement and one of the parties to this Agreement is willing to make or
accept such offer and the other is not, then the unwilling party shall conduct all
further proceedings at its own expense, and shall be responsible for the full amount
of any damages, costs, accounting of profits and settlement costs in excess of those
provided in such offer, but shall be entitled to retain unto itself the benefit of any
litigated or settled result entailing a lower payment of costs, damages, accounting of
profits and settlement costs than that provided in such offer.

8.0 INDEMNITY AND LIMITATION OF LIABILITY:

8.1 The Licensee hereby indemnifies, holds harmless and defends the University, its Board of
Governors, officers, employees, faculty, students, invitees and agents against any and all claims
(including all legal fees and disbursements incurred in association therewith) arising out of the
exercise of any rights under this Agreement including, without limiting the generality of the
foregoing, against any damages or losses, consequential or otherwise, arising from or out of the
use of the Technology or any Improvements or Products licensed under this Agreement by the Licensee
or its sublicensees or their respective customers or end-users howsoever the same may arise.

8.2 Subject to paragraph 8.3, the University’s total liability, whether under the express or
implied terms of this Agreement in tort (including negligence), or at common law, for any loss or
damage suffered by the Licensee, whether direct, indirect or special, or any other similar or like
damage that may arise or does arise from any breaches of this Agreement by the University, its
Board of Governors, officers, employees, faculty, students or agents, shall be limited to the
amount of $5,000.00 (Canadian).

8.3 In no event shall the University be liable for consequential or incidental damages arising from
any breach or breaches of this Agreement.

8.4 No action, whether in contract or tort (including negligence), or otherwise arising out of or
in connection with this Agreement, may be brought by the Licensee more than six months after the
cause of action has occurred.

9.0 PUBLICATION AND CONFIDENTIALITY:

9.1 The Information shall be developed, received and used by the Licensee solely in furtherance of
the purposes set forth in this Agreement subject to the terms and conditions as set forth in this
Article 9.0.

9.2 The Licensee shall keep and use all of the Confidential Information in confidence and will not,
without the University’s prior written consent, disclose any Confidential Information to any person
or entity, except those of the Licensee’s officers, employees, professional adxisors,

 

 

- 9 -

consultants, servants, agents and assigns who require said Confidential Information in
performing their obligations under this Agreement or in connection with services provided to the
Licensee in conjunction with this Agreement. The Licensee covenants and agrees that it will
initiate and maintain an appropriate internal program limiting the internal distribution of the
Confidential Information to its officers, employees, professional advisors, consultants, servants
or agents and to take the appropriate non-disclosure agreements from any and all persons who may
have access to the Confidential Information.

9.3 The Licensee shall not use, either directly or indirectly, any Confidential Information for any
purpose other than as set forth herein without the University’s prior written consent, which
consent shall not be unreasonably withheld.

9.4 In the event that the Licensee is required by judicial or administrative process to disclose
any or all of the Confidential Information, the Licensee shall promptly notify the University and
allow the University reasonable time to oppose such process before disclosing any Confidential
Information.

9.5 Notwithstanding any termination or expiration of this Agreement, the obligations created in
this Article 9.0 shall survive and be binding upon the Licensee, its successors and assigns.

9.6 The University shall not be restricted from presenting at symposia, national or regional
professional meetings, or from publishing in journals or other publications accounts of its
research relating-to the Information, provided that with respect to Confidential Information only,
the Licensee shall have been furnished copies of the disclosure proposed therefor at least 60
calendar days in advance of the presentation or publication date and does not within 30 calendar
days after receipt of the proposed disclosure object to such presentation or publication. Any
objection to a proposed presentation or publication shall specify the portions of the presentation
or publication considered objectionable (collectively the “Objectionable Material”). Upon receipt
of notification from the Licensee that any proposed publication or disclosure contains
Objectionable Material, the University and the Licensee shall work together to revise the proposed
publication or presentation to remove or alter the Objectionable Material in a manner acceptable to
the Licensee, in which case the Licensee shall withdraw its objection. In the event that an
objection is made, disclosure of the Objectionable Material shall not be made for a period of 6
months after the date the Licensee has received the proposed publication or presentation relating
to the Objectionable Material. The University shall co-operate in all reasonable respects in
making revisions to any proposed disclosures if considered by the Licensee to contain Objectionable
Material. The University shall not be restricted from publishing or presenting the proposed
disclosure as long as the Objectionable Material has been removed. After the 6 month period has
elapsed the University shall be free to present and/or publish the proposed publication or
presentation whether or not it contains Objectionable Material.

9.7 The Licensee requires of the University, and the University agrees insofar as it may be
permitted to do so at law, that this Agreement, and each part of it, is confidential and shall not
be disclosed to third parties, as the Licensee claims that such disclosure would or could reveal
commercial, scientific or technical information and would significantly harm the Licensee’s
competitive position and/or interfere with the Licensee’s negotiations with prospective
sublicensees.

 

 

- 10 -

Notwithstanding anything contained in this Article, the parties hereto acknowledge and agree that
the University may identify the title of this Agreement, the parties to this Agreement and the
names of the inventors of the Technology and any Improvements.

10.0 PRODUCTION AND MARKETING:

10.1 The Licensee will not use any of the UBC Trade-marks or make reference to the University or
its name in any advertising or publicity whatsoever, without the prior written consent of the
University, such consent not to be unreasonably withheld, except as required by law. Without
limiting the generality of the foregoing, the Licensee shall not issue a press release with respect
to this Agreement or any activity contemplated herein without the prior review and approval of the
same by the University, such approval not to be unreasonably withheld, except as required by law.
If the Licensee is required by law to act in contravention of this paragraph, the Licensee shall
provide the University with sufficient advance notice in writing to permit the University to bring
an application or other proceeding to contest the requirement.

10.2 The Licensee will not register or use any trade-marks in association with the Products without
the prior written consent of the University, such consent not to be unreasonably withheld.

10.3 The Licensee will pay the University an annual license maintenance fee of $1000.00 (Canadian)
due on the first anniversary of the Date of Commencement and annually thereafter.

11.0 PERFORMANCE_OBLIGATIONS OF THE LICENSEE:

11.1 The Licensee shall use its reasonable commercial efforts to promote, market and sell the
Products and utilize the Technology and any Improvements and to meet or cause to be met the market
demand for the Products and the utilization of the Technology and any Improvements.

11.2 The Licensee will provide the University with a copy of the Licensee’s detailed business plan
and any documents prepared for the purpose of selling securities in the Licensee, prior to the
execution of this Agreement.

11.3 The Licensee will, within three months of the Date of Commencement recruit a board of
directors and the University will have observer status on the board for two years. Such observer
will be entitled to attend all meetings of the Directors of the Licensee and receive copies of all
materials and documents provided to such directors, but shall not be permitted to cast a vote at
such meetings of the Directors.

11.4 On or before the date of execution of this Agreement, the Licensee will provide the University
with written confirmation that the Licensee has raised not less than $1,000,000 (Canadian) through
the sale of its common shares.

11.5 Within six months of the date of execution of this Agreement the Licensee shall recruit a
scientific advisory board conversant with the development objectives of the Licensee and including,
without limitation, at least one clinical practitioner familiar with cancer treatment.

 

 

- 11 -

12.0 REMEDY OF UNIVERSITY FOR BREACH UNDER PARAGRAPH 11.1:

12.1 In the event that the University is of the view that the Licensee is in breach of paragraph
11.1, the University shall notify the Licensee and the parties hereto shall appoint a mutually
acceptable person as an independent evaluator to conduct the evaluation set forth in paragraph
12.2. In the event that the parties cannot agree on such an evaluator, the appointing authority
shall be the British Columbia International Commercial Arbitration Centre.

12.2 The evaluator described in paragraph 12.1 shall review the efforts made by the Licensee
with respect to the promotion, marketing and sale of the Products and the Technology and any
Improvements. If said evaluator determines that the Licensee is in breach of paragraph 11.1,
then the University shall have the right to terminate this Agreement as provided in paragraph
19.1, or to continue the licence granted hereunder as a non-exclusive licence rather than an
exclusive
licence but with all other terms and conditions of this Agreement unchanged. If said evaluator
determines that the Licensee is not in breach of paragraph 11.1, then the University shall
not terminate this Agreement for breach of paragraph 11.1, nor shall it change the nature of
the licence granted hereunder from exclusive to non-exclusive.

12.3 The University may not call for more than one evaluation pursuant to paragraph 12.2 in each
calendar year. The cost of an evaluation hereunder shall be borne 50% by the Licensee and 50% by
the University.

13.0 ACCOUNTING RECORDS:

13.1 The Licensee shall maintain at its principal place of business, or such other place as may
be most convenient, separate accounts and records of business done pursuant to this Agreement,
such accounts and records to be in sufficient detail to enable proper returns to be made under
this Agreement, and the Licensee shall cause its sublicensees to keep similar accounts and
records.

13.2 The Licensee shall retain the accounts and records referred to in paragraph 13.1 above for
at least three years after the date upon which they were made and shall permit any duly
authorized representative of the University to inspect such accounts and records during normal
business hours of the Licensee at the University’s expense. The Licensee shall furnish such
reasonable evidence as such representative will deem necessary to verify the accounting and will
permit such representative to make copies of or extracts from such accounts, records and
agreements at the University’s expense.

13.3 During the term of this Agreement, and thereafter, the University shall use reasonable
efforts to ensure that all information provided to the University or its representatives
pursuant to this Article remains confidential and is treated as such by the University.

 

 

- 12 -

14.0 INSURANCE:

14.1 At least 60 calendar days prior to the first sale of a Product or clinical or other testing
using human subjects using a Product, then the Licensee shall procure and maintain, during the term
of this Agreement, the insurance outlined in paragraphs 14.2 and 14.3 and otherwise comply with the
insurance provisions contained at paragraph 14.2 and 14.3.

14.2 One month prior to the first sale of a Product or clinical or other testing using human
subjects using a Product, the Licensee will give notice to the University of the terms and amount
of the public liability, product liability and errors and omissions insurance which it has placed
in respect of the same, which in no case shall be less than the insurance which a reasonable and
prudent businessman carrying on a similar line of business would acquire. This insurance shall be
placed with a reputable and financially secure insurance carrier, shall include the University, its
Board of Governors, faculty, officers, employees, students, and agents as additional insureds, and
shall provide primary coverage with respect to the activities contemplated by this Agreement. Such
policy shall include severability of interest and cross-liability clauses and shall provide that
the policy shall not be cancelled or materially altered except upon at least 30 calendar days’
prior written notice to the University. The University shall have the right to require reasonable
amendments to the terms or the amount of coverage contained in the policy. Failing the parties
agreeing on the appropriate terms or the amount of coverage, then the matter shall be determined by
arbitration as provided for herein. The Licensee shall provide the University with certificates of
insurance evidencing such coverage no later than 7 calendar days before commencement of sales of
any Product or clinical or other testing using human subjects using a Product and the Licensee
covenants not to sell any Product before such certificate is provided and approved by the
University, or to sell or test any Product at any time unless the insurance outlined in this
paragraph 14.2 is in effect.

14.3 The Licensee shall require that each sublicensee under this Agreement shall procure and
maintain, during the term of the sublicense, public liability, product liability and errors and
omissions insurance in reasonable amounts, with a reputable and financially secure insurance
carrier. The Licensee shall use its best efforts to ensure that any and all such policies of
insurance required pursuant to this clause shall contain a waiver of subrogation against the
University, its Board of Governors, faculty, officers, employees, students, and agents.

15.0 ASSIGNMENT:

15.1 The Licensee will not assign, transfer, mortgage, charge or otherwise dispose of any or all of
the rights, duties or obligations granted to it under this Agreement without the prior written
consent of the University, such consent not to be unreasonably withheld.

15.2 The University shall have the right to assign its rights, duties and obligations under this
Agreement to a company or society of which it is the sole shareholder, in the case of a company or
of which it controls the membership, in the case of a society. In the event of such an assignment,
the Licensee will release, remise and forever discharge the University from any and all obligations
or covenants, provided however that such company or society, as the case may be, executes a written
agreement which provides that such company or society shall assume all such obligations or

 

 

- 13 -

covenants from the University and that the Licensee shall retain all rights granted to the
Licensee pursuant to this Agreement.

16.0 GOVERNING LAW AND ARBITRATION:

16.1 This Agreement shall be governed by and construed in accordance with the laws of the Province
of British Columbia and the laws of Canada in force therein without regard to its conflict of law
rules. All parties agree that by executing this Agreement they have attorned to the jurisdiction of
the Supreme Court of British Columbia. Subject to paragraphs 16.2 and 16.3, the British Columbia
Supreme Court shall have exclusive jurisdiction over this Agreement.

16.2 In the event of any dispute arising between the parties concerning this Agreement, its
enforceability or the interpretation thereof, the same shall be settled by a single arbitrator
appointed pursuant to the provisions of the Commercial Arbitration Act of British Columbia, or any
successor legislation then in force. The place of arbitration shall be Vancouver, British Columbia.
The language to be used in the arbitration proceedings shall be English.

16.3 Clause 16.2 of this Article shall not prevent a party hereto from applying to a court of
competent jurisdiction for interim protection such as, by way of example, an interim injunction.

17.0 NOTICES:

17.1 All payments, reports and notices or other documents that any of the parties hereto are
required or may desire to deliver to any other party hereto may be delivered only by personal
delivery or by registered or certified mail, telex or telecopy, all postage and other charges
prepaid, at the address for such party set forth below or at such other address as any party may
hereinafter designate in writing to the other party. Any notice personally delivered or sent by
telex or telecopy shall be deemed to have been given or received at the time of delivery, telexing
or telecopying. Any notice mailed as aforesaid shall be deemed to have been received on the
expiration of 5 calendar days after it is posted, provided that if there shall be at the time of
mailing or between the time of mailing and the actual receipt of the notice a mail strike, slow
down or labour dispute which might affect the delivery of the notice by the mails, then the notice
shall only be effected if actually received.

	 	 	 
	If to the University:

	 	The Managing Director
	

	 	University — Industry Liaison Office
	

	 	University of British Columbia
	

	 	IRC 331 — 2194 Health Sciences Mall
	

	 	Vancouver, BC V6T 1Z3
	

	 	Telephone: (604) 822-8580
	

	 	Telecopier: (604) 822-8589

 

 

- 14 -

	 	 	 
	If to the Licensee:

	 	CEO
	

	 	GENEMAX PHARMACEUTICALS INC.,
	

	 	1260 – 999 West Hastings Street,
	

	 	Vancouver, BC V6C 2W2
	

	 	Telephone: (604) 683 6640
	

	 	Telecopier: (604) 683 6650
	 
	If to Jefferies:

	 	Dr. Wilfred A. Jefferies, Professor
	

	 	2222 Health Sciences Mall
	

	 	Vancouver, BC V6T 1Z3
	

	 	Telephone: (604)822-6961
	

	 	Telecopier: (604) 822-7815

18.0 TERM:

18.1 This Agreement and the licence granted hereunder shall terminate on the expiration of a terra
of 15 years from the Date of Commencement or the expiration of the last patent obtained pursuant to
Article 7 herein, whichever event shall last occur, unless earlier terminated pursuant to Article
19 herein.

19.0 TERMINATION:

19.1 This Agreement shall automatically and immediately terminate without notice to the. Licensee
if any proceeding under the Bankruptcy and Insolvency Act of Canada, or any other statute of
similar purport, is commenced by or against the Licensee.

19.2 The University may, at its option, terminate this Agreement immediately on the happening of
any one or more of the following events by delivering notice in writing to that effect to the
Licensee:

	 	(1)  	if the Licensee becomes insolvent;
	 
	 	(2)  	if any execution, sequestration, or any other process of any court becomes
enforceable against the Licensee or if any such process is levied on the rights under
this Agreement or upon any of the monies due to the University and is not released or
satisfied by the Licensee within 30 calendar days thereafter;
	 
	 	(3)  	if any resolution is passed or order made or other steps taken for the winding
up, liquidation or other termination of the existence of the Licensee;
	 
	 	(4)  	if the Licensee is more than 30 calendar days in arrears of any monies that are
due to the University under the terms of this Agreement;
	 
	 	(5)  	if the Technology or any Improvements becomes subject to any security interest,
lien, charge or encumbrance in favour of any third party claiming through the Licensee;

 

 

- 15 -

	 	(6)  	if the Licensee ceases or threatens to cease to carry on its business;
	 
	 	(7)  	if any part of the Licensee’s business relating to this Agreement is
transferred to a subsidiary or associated company without the prior written consent
of the University, such consent not to be unreasonably withheld except as provided
in paragraph 19.3;
	 
	 	(8)  	if the Licensee commits any breach of any of paragraphs 4.1, 10.1, 10.2 and 14;
	 
	 	(9)  	if it is determined, pursuant to paragraph 12.2, that the Licensee is
in breach of paragraph 11.1; or
	 
	 	(10)  	if any sublicensee of the Licensee is in breach of its sublicence
agreement with the Licensee and the Licensee does not cause such sublicensee to
cure such default within 30 calendar days of receipt of written notice from the
University requiring that the Licensee cause such sublicensee to cure such default,
or failing such cure terminate such sublicense.

19.3 The University shall not withhold its consent pursuant to subparagraph 19.2(g) unless
the granting of such consent would result in the University having a contractual relationship
with an entity with whom the University is prohibited from contracting with pursuant to its
then existing policies.

19.4 Other than as set out in paragraphs 19.1 and 19.2, if either party shall be in default
under or shall fail to comply with the terms of this Agreement then the non-defaulting party
shall have the right to terminate this Agreement by written notice to that effect if:

	 	(1)  	such default is reasonably curable within 30 calendar days after
receipt of notice of such default and such default or failure to comply is not
cured within 30 calendar days after receipt of written notice thereof, or
	 
	 	(2)  	such default is not reasonably curable within 30 calendar days after
receipt of written notice thereof, and such default or failure to comply is not
cured within such further reasonable period of time as may be necessary for the
curing of such default or failure to comply.

19.5 If this Agreement is terminated pursuant to any of paragraphs 19.1, 19.2, or 19.4, the
Licensee shall make any payments accrued to the University prior to termination as set out in
paragraphs 6.3 and 10.3 , and the University may proceed to enforce payment of all outstanding
payment owed to the University and to exercise any or all of the rights and remedies contained
herein or otherwise available to the University by law or in equity, successively or
concurrently, at the option of the University. Upon any such termination of this Agreement, the
Licensee shall forthwith deliver up to the University all Technology and any Improvements in
its possession or control and shall have no further right of any nature whatsoever in the
Technology or any Improvements. On the failure of the Licensee to so deliver up the Technology
and any Improvements, the University may immediately and without notice enter the Licensee’s
premises and take possession of the Technology and any Improvements. The Licensee will pay all
charges

 

 

- 16 -

or expenses incurred by the University in the enforcement of its rights or remedies against the
Licensee and including, without limitation, the University’s legal fees and disbursements on an
indemnity basis.

19.6 The Licensee shall cease to use the Technology or any Improvements in any manner whatsoever
or to manufacture or sell the Products within 5 calendar days from the Effective Date of
Termination. The Licensee shall then deliver or cause to be delivered to the University an
accounting within 30 days from the Effective Date of Termination. The accounting will specify, in
or on such terms as the University may in its sole discretion require, the inventory or stock of
Products manufactured and remaining unsold on the Effective Date of Termination. The University
will instruct that the unsold Products be stored, destroyed, or sold under its direction,
provided the Agreement was terminated pursuant to paragraphs 19.2 or 19.4. Without limiting the
generality of the foregoing, if the Agreement was terminated pursuant to paragraph 19.1, the
unsold Products will not be sold by any party without the prior written consent of the
University.

19.7 Notwithstanding the termination of this Agreement, paragraph 13.1 shall remain in full force
and effect until three years after any other claim or claims of any nature or kind whatsoever of
the University against the Licensee has been settled.

20.0 MISCELLANEOUS COVENANTS OF LICENSEE:

20.1 The Licensee hereby represents and warrants to the University that the Licensee is a
corporation duly organized, existing and in good standing under the laws of the State of Delaware
and has the power, authority and capacity to enter into this Agreement and to carry out the
transactions contemplated by this Agreement, all of which have been duly and validly authorized
by all requisite corporate proceedings.

20.2 The Licensee represents and warrants that it has the expertise necessary to handle the
Technology and any Improvements with care and without danger to the Licensee, its employees,
agents, or the public. The Licensee shall not accept delivery of the Technology or any
Improvements until it has requested and received from the University all necessary information
and advice to ensure that it is capable of handling the Technology and any Improvements in a safe
and prudent manner.

20.3 The Licensee shall comply with all laws, regulations and ordinances, whether Federal,
Provincial, Municipal or otherwise, with respect to the Technology and any Improvements and/or
this Agreement.

20.4 Upon the presentation of itemized bills to the Licensee by the University, the Licensee
shall pay all reasonable legal expenses and costs incurred by the University in respect of any
consents and approvals required from the University in connection with the entering into of this
Agreement, and including but not limited to expenses and costs in respect of the University’s
review of any sublicences to be granted by the Licensee.

20.5 The Licensee shall pay all taxes and any related interest or penalty howsoever designated
and imposed as a result of the existence or operation of this Agreement, and including,

 

 

- 17 -

but not limited to, tax which the Licensee is required to withhold or deduct from payments to the
University. The Licensee will furnish to the University such evidence as may be required by
Canadian authorities to establish that any such tax has been paid. If the University is required
to collect a tax to be paid by the Licensee or any of its sublicensees, the Licensee shall pay
such tax to the University on demand.

21.0 COVENANTS OF JEFFERIES

21.1 Jefferies acknowledges that under the terms of his employment with the University, the
Technology and any Improvements are the property of the University and pursuant to the University’s
Patent and Licensing Policy, he is entitled to certain present benefits and possible future
benefits arising from the commercialization of the Technology, and Jefferies acknowledges and
agrees that he has elected to and does hereby waive his entitlement to all such benefits
absolutely.

21.2 Jefferies acknowledges that any Improvements with respect to the Technology which are
developed, invented or discovered while Jefferies is an employee of the University shall be the
absolute property of the University and shall become a part of and be subject to the terms of this
Agreement.

21.3 By electing to waive his entitlement in all benefits accruing under the Patent and Licensing
Policy as referred to in paragraph 21. 1 above, and by entering into this Agreement, Jefferies
acknowledges that he has not sought nor been given any legal advice by any University employee nor
the University’s legal counsel.

22.0 GENERAL:

22.1 The Licensee shall permit any duly authorized representative of the University, during normal
business hours and at the University’s sole risk and expense, to enter upon and into any premises
of the Licensee for the purpose of inspecting the Products and the manner of their manufacture and
generally of ascertaining whether or not the provisions of this Agreement have been, are being, or
will be complied with by the Licensee.

22.2 Nothing contained herein shall be deemed or construed to create between the parties hereto a
partnership or joint venture. No party shall have the authority to act on behalf of any other
party, or to commit any other party in any manner or cause whatsoever or to use any other party’s
name in any way not specifically authorized by this Agreement. No party shall be liable for any
act, omission, representation, obligation or debt of any other party, even if informed of such act,
omission, representation, obligation or debt.

22.3 Subject to the limitations hereinbefore expressed, this Agreement shall enure to the benefit
of and be binding upon the parties and their respective successors and permitted assigns.

22.4 No condoning, excusing or overlooking by any party of any default, breach or non-observance by
any other party at any time or times in respect of any covenants, provisos or conditions of this
Agreement shall operate as a waiver of such party’s rights under this Agreement in respect of any
continuing or subsequent default, breach or non-observance, so as to defeat in any

 

 

- 18 -

way the rights of such party in respect of any such continuing or subsequent default or breach,
and no waiver shall be inferred from or implied by anything done or omitted by such party, save
only an express waiver in writing.

22.5 No exercise of a specific right or remedy by any party precludes it from or prejudices it in
exercising another right or pursuing another remedy or maintaining an action to which it may
otherwise be entitled either at law or in equity.

22.6 Marginal headings as used in this Agreement are for the convenience of reference only and do
not form a part of this Agreement and are not be used in the interpretation hereof.

22.7 The terms and provisions, covenants and conditions contained in this Agreement which by the
terms hereof require their performance by the parties hereto after the expiration or termination of
this Agreement shall be and remain in force notwithstanding such expiration or other termination of
this Agreement or any provisions thereof for any reason whatsoever.

22.8 In the event that any Article, section, clause, paragraph or subparagraph of this Agreement
shall be held to be indefinite, invalid, illegal or otherwise voidable or unenforceable, the entire
agreement shall not fail on account thereof, and the balance of the Agreement shall continue in
full force and effect.

22.9 The parties hereto acknowledge that the law firm of Richards Buell Sutton has acted solely for
the University in connection with this Agreement and that the Licensee have been advised to seek
independent legal advice in connection with its review and execution of this Agreement.

22.10 This Agreement sets forth the entire understanding between the parties and no modifications
hereof shall be binding unless executed in writing by the parties hereto.

22.11 Time shall be of the essence of this Agreement.

 

 

- 19 -

22.12 Whenever the singular or masculine or neuter is used throughout this Agreement the
same shall be construed as meaning the plural or feminine or body corporate when the context or the
parties hereto may require.

     IN WITNESS WHEREOF the parties hereto have hereunto executed this Agreement on the 6
day of  March, 2000 but effective as of the Date of
Commencement.

	 	 	 	 	 
	SIGNED FOR AND ON BEHALF OF

	 	 	)	 
	The University of British Columbia

	 	 	)	 
	by its duly authorized officers:

	 	 	)	 
	 

	 	 	)	 
	/s/ Angus Livingstone

	 	 	)	 
	

	 	 	)	 
	Authorized Signatory

	 	 	)	 
	 

	 	 	)	 
	

	 	 	)	 
	Authorized Signatory

	 	 	)	 
	 
	 	 	 	 
	SIGNED FOR AND BEHALF OF

	 	 	)	 
	Genemax Pharmaceuticals Inc. 

	 	 	)	 
	by its duly authorized officer:

	 	 	)	 
	 

	 	 	)	 
	/s/ Ronald L. Handford

	 	 	)

)	 
	Authorized Signatory

	 	 	)	 

	 	 	 	 	 	 	 
	WITNESSED BY: 

	 	 	)

)	 	 	 
	/s/ P. R. Wells

	 	 	)	 	 	/s/ Wilfred A. Jefferies
	

Signature  P. R. WELLS.

	 	 	)

)	 	 	
 Dr.
Wilfred A. Jefferies
	                  UBC

	 	 	)	 	 	 
	

	 	 	)	 	 	 
	Address    IRC 331- 2194

	 	 	)	 	 	 
	                  Health Science Mall

	 	 	)	 	 	 
	

	 	 	)	 	 	 
	                 Vancover V6T 123

	 	 	)	 	 	 

 

 

- 20 -

SCHEDULE“A” 

DESCRIPTION OF “TECHNOLOGY”

UILO 95-015 Method of Enhancing Expression of MHC-Class 1 Molecules Bearing Endogenous Peptides and
any and all improvements, variations, updates, modifications, and enhancements thereto, and

UILO 95-010 Method of Identifying MHC-Class 1 Restricted Antigens Endogenously Processed by a
Cellular Secretory Pathway and any and all improvements, variations, updates, modifications, and
enhancements thereto

Patent numbers:

UILO 95-015

US SN 08/817,731 (Application)

Japan SN 510486/1996 (Application)

Europe Designating: France, UK, Germany, Switzerland

SN 95931866.8 (Application)

UILO 95-010

US 5,792,604 (Issued)

Japan SN 532142/1997 (Application)

Europe, Designating all countries: EP 97906062.1 (Application)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]